SCHEMBL20139150

SCHEMBL20139150

O=C(O)N1CCN(c2nc(-c3scnc3Cl)[nH]c(=O)c2Cl)CC(F)C1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 1/20 0.31
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139135 0.83 KRAS (0.31) KRASCXCR3
SCHEMBL21531638 0.83 PI4KB (0.34) KRAS
SCHEMBL20138914 0.81
SCHEMBL20143005 0.81
SCHEMBL20138763 0.81
Hydrochloric Acid SCHEMBL21531626 0.80
SCHEMBL21853826 0.77 KCNH2 (0.36)
SCHEMBL20154098 0.77 KIT (0.40)
SCHEMBL20139151 0.74 MGLL (0.30)
SCHEMBL20154093 0.72 POLB (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538523-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS Cancer Research Technology Limited (GB) 2019-09-18 EP disclosed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 WO disclosed